Navigation Links
Epilepsy Drugs' Risk of Birth Defects May Be Dose-Dependent
Date:6/6/2011

SUNDAY, June 5 (HealthDay News) -- Four of the most frequently prescribed epilepsy drugs appear to increase the risk of serious birth defects when taken early in pregnancy, a new study finds.

And the higher the dosage, the greater the risk, the international team of researchers reported in the June 6 online edition of The Lancet Neurology.

"Our results show that dose selection is as crucial as the choice of drug," the authors said in a journal news release. Their study gives doctors the opportunity to prescribe the safest anti-seizure medication at the safest level for women with epilepsy who want to get pregnant, they said.

The drugs studied were carbamazepine (Tegretol, Epitol), lamotrigine (Lamictal), valproic acid (Depakote), and phenobarbital.

The rate of birth defects was higher with increased dose for all the drugs, the researchers said, but they emphasized that the vast majority of women in their study delivered healthy children.

Most women with epilepsy need to take anti-seizure medication or risk harming themselves or their baby. Previous studies found that valproic acid, in particular, might increase the risk of birth defects, but those studies didn't look at individual doses. Nor did they take into account other influential factors, such as family history of birth defects or severity of epilepsy.

"Present guidelines caution on the use of valproic acid during pregnancy, but offer little guidance on alternative options and how to manage women whose seizures cannot be controlled by other drugs," Dr. Torbjorn Tomson, of the Karolinska Institute in Stockholm, Sweden, and colleagues, said in the news release.

For their 11-year study, the researchers used data from the International Registry of Antiepileptic Drugs and Pregnancy on nearly 4,000 pregnancies in 33 countries.

In all, 230 pregnancies resulted in major birth defects by the end of the first year after birth.

Low doses of lamotrigine (less than 300 milligrams [mg] per day) and carbamazepine (less than 400 mg per day) carried the smallest risk, the investigators found.

The greatest risk to the fetus was seen with the highest doses of valproic acid (1,500 mg a day or more) and phenobarbital (150 mg or more a day), the researchers said.

A family history of major birth defects quadrupled the risk, they found.

"The findings are important to the clinician treating people with epilepsy because they provide specific information not only on the drug but also on the dose," Dr. W. Allen Hauser, a professor of neurology and epidemiology at Columbia University in New York City, said in an accompanying editorial.

"It is easy to recommend against use of a specific drug (valproic acid, for instance) because of a higher risk of malformations, but if seizure control is not possible with alternative therapeutic regimens, such recommendations are difficult to implement," he continued.

"Incidence of major congenital malformations associated with a low dose of a higher-risk drug might be lower than that associated with a high dose of a lower-risk drug," Hauser added.

Commenting on the study, Dr. Jennifer Wu, an obstetrician/gynecologist with Lenox Hill Hospital in New York City, said: "This new study gives doctors and epileptic patients more information about safer drug choices. Patients with epilepsy should always try to plan their pregnancies. Some patients will be able to come off their medications, some patients will lower their dosages, and some patients will switch medications. This should all be done in the non-pregnant state."

More information

For more about epilepsy, visit the U.S. National Library of Medicine.

-- HealthDay Staff

SOURCES: June 6, 2011, The Lancet Neurology, online; Jennifer Wu, M.D., obstetrician/gynecologist, Lenox Hill Hospital, New York City


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Oldest Epilepsy Drug Best for Children
2. New study identifies best treatment for childhood epilepsy
3. Implant Shows Promise for Hard-to-Treat Epilepsy
4. Purple Day March 26th: The United States Goes Purple in Support of Epilepsy Awareness
5. Fetal alcohol spectrum disorder linked to high prevalence of epilepsy, Queens study
6. Gene Mutation Ups Risk of Sudden Death in People with Epilepsy
7. Children with epilepsy say their quality of life is better than their parents think
8. University Hospitals Neurological Institute hosts international epilepsy colloquium
9. Altered brain development found in children with newly diagnosed epilepsy
10. Children With Epilepsy Feel on Par With Healthy Siblings
11. Study confirms favorable long-term prognosis of epilepsy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Epilepsy Drugs' Risk of Birth Defects May Be Dose-Dependent
(Date:3/23/2017)... ... March 23, 2017 , ... ... Angeles based healthcare technology company California Healthcom Group (CHG). , The HUG ... healthcare arena. With headquarters in California, CHG is a growing, internationally recognized healthcare ...
(Date:3/23/2017)... ... March 23, 2017 , ... Michael Lanteri Agency, an insurance ... Collins area, has unveiled a collaboration with nonprofit Big Bones Canine Rescue as ... worthy cause may now be made at http://bigbonescaninerescue.com/ . , Big Bones ...
(Date:3/23/2017)... Laguna Hills, CA (PRWEB) , ... March 23, ... ... in document management and workflow solutions, today named The Resource Group as their ... annual customer and partner conference in Newport Beach, CA. The award recognizes ...
(Date:3/23/2017)... ... , ... Sharon Kleyne, host of the nationally syndicated radio program, The Sharon ... talked on her program about how she is looking forward to World Water Day ... important distinction. World Water Day, Kleyne pointed out, is an occasion for looking ahead ...
(Date:3/23/2017)... , ... March 23, 2017 , ... It’s that time ... many students are thinking about summer internships , which can be frustrating when ... The pros at Garden Media Group, a boutique public relations firm outside of Philadelphia, ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 23, 2017  Cornerstone Pharmaceuticals, Inc., a ... milestone today.  Following successful End-of-Phase I (EOP1) ... and Drug Administration (FDA), the Company has ... path forward to conduct pivotal trials of ... acute myeloid leukemia (AML) and pancreatic cancer. ...
(Date:3/23/2017)... March 23, 2017 Piramal ... Limited, anuncia el nombramiento de Stuart E. ... plataforma de servicios integrados completa para su base ... cargo clave en el crecimiento y ejecución de ... responsable de impulsar todas las actividades de desarrollo ...
(Date:3/23/2017)... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... a Phase 1 study of MM-310 in solid tumors. ... novel taxane and targets the EphA2 receptor, a protein ... major tumor types, including prostate, ovarian, bladder, gastric, pancreatic ... study is an important step in evaluating MM-310,s safety ...
Breaking Medicine Technology: